Celastrol is a powerful natural compound with anti-inflammatory potential, but its toxicity limits clinical use. This paper tackles that problem through structural modification.
The researchers developed celastrol derivatives and identified COM5 and COM6 as promising candidates. These compounds kept strong anti-arthritic activity while showing much lower toxicity than celastrol. In arthritis models, they reduced paw swelling, arthritis scores, bone erosion, synovial overgrowth, immune-cell infiltration, and cartilage loss. They also helped restore the balance between pro-inflammatory Th17 cells and regulatory T cells.
The study links these effects to calcium signaling. COM5, in particular, targeted SERCA, a calcium pump that helps control calcium balance inside cells. Both COM5 and COM6 also influenced calcium-associated inflammatory genes and unfolded protein response
pathways. This suggests that RA inflammation is not only an immune-cell problem; it is also connected to how stressed joint cells handle calcium and protein-folding pressure.
The novelty of this paper lies in combining natural-product chemistry with immune and cellular stress biology. It does not simply report another anti-inflammatory compound. It shows how modifying a known molecule can preserve useful activity while reducing harm.
For the cluster topic of immune tolerance, this paper expands the meaning of immune rebalancing. Tolerance can be disturbed when cells are under stress and send inflammatory signals. By controlling calcium-related stress pathways, safer celastrol derivatives may help reduce the signals that keep the immune system overactive in RA.
References
L. Wang et al., “N-Acetylcysteine overcomes epalrestat-mediated increase of toxic 4-hydroxy-2-nonenal and potentiates the anti-arthritic effect of epalrestat in AIA model,” International Journal of Biological Sciences, vol. 19, no. 13, pp. 4082–4102, 2023. Doi: 10.7150/ijbs.85028
